JP7457880B2 - 新規なＮａｖ１．７モノクローナル抗体 - Google Patents

新規なＮａｖ１．７モノクローナル抗体 Download PDF

Info

Publication number
JP7457880B2
JP7457880B2 JP2023556697A JP2023556697A JP7457880B2 JP 7457880 B2 JP7457880 B2 JP 7457880B2 JP 2023556697 A JP2023556697 A JP 2023556697A JP 2023556697 A JP2023556697 A JP 2023556697A JP 7457880 B2 JP7457880 B2 JP 7457880B2
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
deleted
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023556697A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023074888A5 (https=
JPWO2023074888A1 (https=
Inventor
舞 吉川
順二 小野田
大貴 中森
竜也 高橋
えりか 葛西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of JPWO2023074888A1 publication Critical patent/JPWO2023074888A1/ja
Publication of JPWO2023074888A5 publication Critical patent/JPWO2023074888A5/ja
Application granted granted Critical
Publication of JP7457880B2 publication Critical patent/JP7457880B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023556697A 2021-11-01 2022-10-31 新規なＮａｖ１．７モノクローナル抗体 Active JP7457880B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2021178982 2021-11-01
JP2021178982 2021-11-01
JP2022005967 2022-01-18
JP2022005967 2022-01-18
PCT/JP2022/040580 WO2023074888A1 (ja) 2021-11-01 2022-10-31 新規なＮａｖ１．７モノクローナル抗体

Publications (3)

Publication Number Publication Date
JPWO2023074888A1 JPWO2023074888A1 (https=) 2023-05-04
JPWO2023074888A5 JPWO2023074888A5 (https=) 2024-03-01
JP7457880B2 true JP7457880B2 (ja) 2024-03-28

Family

ID=86159498

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023556697A Active JP7457880B2 (ja) 2021-11-01 2022-10-31 新規なＮａｖ１．７モノクローナル抗体

Country Status (12)

Country Link
US (1) US20250163145A1 (https=)
EP (1) EP4428239A4 (https=)
JP (1) JP7457880B2 (https=)
KR (1) KR102753603B1 (https=)
AU (1) AU2022377536B2 (https=)
CA (1) CA3236404A1 (https=)
CO (1) CO2024003915A2 (https=)
IL (1) IL311683B2 (https=)
MX (1) MX2024004393A (https=)
MY (1) MY206945A (https=)
TW (1) TWI867354B (https=)
WO (1) WO2023074888A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024225446A1 (ja) * 2023-04-28 2024-10-31 塩野義製薬株式会社 新規なＮａｖ１．７モノクローナル抗体を含む医薬組成物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013508443A (ja) 2009-10-27 2013-03-07 ユセベ ファルマ ソシエテ アノニム イオンチャネルに対する抗体
JP2013507980A (ja) 2009-10-27 2013-03-07 ユセベ ファルマ ソシエテ アノニム 機能改変するＮａｖ１．７抗体
JP2016512430A (ja) 2013-03-14 2016-04-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｎａｖ１．７に対するヒト抗体
WO2019230856A1 (ja) 2018-05-31 2019-12-05 塩野義製薬株式会社 Ｎａｖ１．７モノクローナル抗体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214973B1 (en) 1993-11-19 2001-04-10 Chugai Seiyaku Kabushiki Kaisha Reshaped human antibody to human medulloblastoma cells
DE69535243T2 (de) 1994-07-13 2007-05-10 Chugai Seiyaku K.K. Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
EP0962467A4 (en) 1996-09-26 2002-10-30 Chugai Pharmaceutical Co Ltd Antibody against human parathormone related peptides
JP2016529909A (ja) * 2013-09-05 2016-09-29 デューク ユニバーシティ Ｎａｖ１．７抗体及び前記抗体を使用する方法
GB2517953A (en) 2013-09-05 2015-03-11 Argen X Bv Antibodies to complex targets
US20240002497A1 (en) 2020-11-19 2024-01-04 Merck Sharp & Dohme Llc Nav1.7 binders
WO2024225446A1 (ja) * 2023-04-28 2024-10-31 塩野義製薬株式会社 新規なＮａｖ１．７モノクローナル抗体を含む医薬組成物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013508443A (ja) 2009-10-27 2013-03-07 ユセベ ファルマ ソシエテ アノニム イオンチャネルに対する抗体
JP2013507980A (ja) 2009-10-27 2013-03-07 ユセベ ファルマ ソシエテ アノニム 機能改変するＮａｖ１．７抗体
JP2016512430A (ja) 2013-03-14 2016-04-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｎａｖ１．７に対するヒト抗体
WO2019230856A1 (ja) 2018-05-31 2019-12-05 塩野義製薬株式会社 Ｎａｖ１．７モノクローナル抗体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BANG, Sangsu et al.，Differential Inhibition of Nav1.7 and Neuropathic Pain by Hybridoma-Produced and Recombinant Monoclonal Antibodies that Target Nav1.7，Neurosci. Bull.，2018年，34(1)，p. 22-41
LIU, Dong et al.，Evaluation of recombinant monoclonal antibody SVmab1 binding to Nav1.7 target sequences and block of human Nav1.7 currents [version 1;referees:3 approved]，F1000Research，2016年，5，2764

Also Published As

Publication number Publication date
KR102753603B1 (ko) 2025-01-13
CA3236404A1 (en) 2023-05-04
JPWO2023074888A1 (https=) 2023-05-04
WO2023074888A1 (ja) 2023-05-04
TWI867354B (zh) 2024-12-21
EP4428239A4 (en) 2025-10-29
IL311683B2 (en) 2026-04-01
IL311683B1 (en) 2025-12-01
KR20240099394A (ko) 2024-06-28
MY206945A (en) 2025-01-21
TW202325739A (zh) 2023-07-01
AU2022377536A1 (en) 2024-04-11
EP4428239A1 (en) 2024-09-11
AU2022377536B2 (en) 2024-10-24
MX2024004393A (es) 2024-04-30
US20250163145A1 (en) 2025-05-22
IL311683A (en) 2024-05-01
CO2024003915A2 (es) 2024-04-18

Similar Documents

Publication Publication Date Title
JP2024167313A (ja) 腫瘍治療薬及びその応用
US20200347130A1 (en) CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use Thereof
WO2021027674A1 (zh) 一种含有抗体的肿瘤治疗剂的开发和应用
US11643458B2 (en) Monoclonal antibody against Nav1.7
US20220204610A1 (en) Protein binders for irhom2
JP7377185B2 (ja) 抗ヒトｔｌｒ７抗体
CN104011206B (zh) 新型抗人ctgf抗体
CN112243443B (zh) 抗trop-2抗体、其抗原结合片段及其医药用途
JP7457880B2 (ja) 新規なＮａｖ１．７モノクローナル抗体
WO2024225446A1 (ja) 新規なＮａｖ１．７モノクローナル抗体を含む医薬組成物
US20240383974A1 (en) Bispecific antibody and application thereof
CA3249959A1 (en) ANTI-CXCL1 HUMAN ANTIBODY
HK40110725A (en) Novel nav1.7 monoclonal antibody
JP7202011B2 (ja) 抗ｒａｍｐ２抗体
CN107840886B (zh) Gm-csf抗体及其用途
BR112024005503B1 (pt) Anticorpo monoclonal ou seu fragmento de anticorpo que se liga especificamente a nav1.7 humana
CN118119711A (zh) 新的Nav1.7单克隆抗体
RU2776821C2 (ru) Моноклональное антитело к nav1.7
WO2025113639A1 (zh) 抗gdf15的抗体及其方法和用途
JP2025535498A (ja) Ｃｄ２４に対する抗体およびその使用
CN119301153A (zh) 结合il-17a和il-17f的抗体分子及其应用
HK40113191A (zh) 犬白介素-31受体αI的犬源化抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240115

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20240115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240306

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240312

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240315

R150 Certificate of patent or registration of utility model

Ref document number: 7457880

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150